ATHE
Alterity Therapeutics Limited
Healthcare — Biotechnology
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Price History
Fundamentals
| Market Cap | $97.33M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.43 |
| EPS (TTM) | $-0.62 |
| Dividend Yield | - |
| Profit Margin | -219.85% |
| Revenue Growth | 74.60% |
| ROE | -47.02% |
| Debt/Equity | 0.18 |
| Recommendation | Strong Buy 1.5 |
| Analyst Target | $11.00 |
| Analysts | 2 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 72.0 |
| Beta | -0.01 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.00 |
| 52-Week Low | $2.66 |
| 50-Day Avg | $4.47 |
| 200-Day Avg | $3.88 |
| Avg Volume | 49.9K |
| Volume | 11.6K |
Performance Analysis
NEUTRALATHE presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report